XOMA Royalty (NASDAQ:XOMA) Stock, Quote.Headers.trade-ideas

XOMA Royalty

XOMA

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

zvra

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ZVRA

FDA&#39;s Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics&#39; arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.

FDA Convenes Expert Panel Meeting For Zevra Therapeutics&#39; Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

Earnings Misses

Penny Stocks

Small Cap

Markets

LXRX

Lexicon Pharmaceuticals (NASDAQ: LXRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.

Lexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue Estimates

cancer

KNTE

XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.

Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma

XOMA Royalty Corp

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $123 price target.</p>


Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $123 Price Target

<p>XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $120.0, a high estimate of $123.00, and a low estimate of $117.00. Observing a 2.56% increase, the current average has risen from the previous average price target of $117.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733259665_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive XOMA Royalty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$117.00</td>
<td>$117.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to XOMA Royalty. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of XOMA Royalty compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of XOMA Royalty's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into XOMA Royalty's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on XOMA Royalty analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into XOMA Royalty's Background</h2>
<p>XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.</p>
<h3>A Deep Dive into XOMA Royalty's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> XOMA Royalty's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-11.57%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> XOMA Royalty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-2535.56%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> XOMA Royalty's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-20.15%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> XOMA Royalty's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-7.98%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.4</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   maintains XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and raises the price target from $117 to $123.</p>


HC Wainwright & Co. Maintains Buy on XOMA Royalty, Raises Price Target to $123

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and raises the price target from $117 to $123.</p>


HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Raises Price Target to $123

WIIM

XOMA Royalty shares are trading higher after the company announced its economic interest in Seralutinib, a Phase 3 asset studying pulmonary arterial hypertension.

<ul>
<li>In addition, XOMA Royalty will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders. &nbsp;XOMA Royalty's net royalties will range from the low to mid-single digits on commercial sales; additionally, the Company will retain up to $25 million of the milestone payments.&nbsp;</li>
</ul>


XOMA Royalty Said It Owns An Economic Interest In Seralutinib, A Phase 3 Asset Being Studied In Pulmonary Arterial Hypertension, Through Its Acquisition Of Pulmokine For A $20M In Cash Payment

<p>XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) reported quarterly losses of $(1.59) per share which missed the analyst consensus estimate of $(0.44) by 261.36 percent.  The company reported quarterly sales of $9.197 million which beat the analyst consensus estimate of $6.493 million by 41.65 percent.  This is a 1.01K percent increase over sales of $830.000 thousand the same period last year.</p>


Earnings

Earnings Beats

XOMA Q3 2024 GAAP EPS $(1.59) Misses $(0.44) Estimate, Sales $9.197M Beat $6.493M Estimate

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $117 price target.</p>


HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $117 Price Target

TWST

Twist Bioscience Enters Royalty Purchase Agreement With XOMA Royalty; XOMA To Provide Twist With $15M Upfront Payment In Exchange For Right To Receive Half Of Future Potential Milsetones Earned Under Antibody Discovery And Biopharma Services Collaborations

XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones

<p>XOMA Royalty Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock:<br /><br />&nbsp;</p>
<p>Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAP#NASDAQ">XOMAP</a>) shall receive a cash dividend equal to $0.53906 per share.&nbsp;&nbsp;</p>
<p>Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAO#NASDAQ">XOMAO</a>), shall receive a cash dividend equal to $0.52344 per depositary share.&nbsp;&nbsp;</p>
<p>The preferred dividends will be paid on or about October 15, 2024, to respective holders of record at the close of business on October 3, 2024.&nbsp;&nbsp;</p>


Dividends

XOMAO

XOMAP

XOMA Announces $0.53906 for Series A, $0.52344 for Series B Preferred Dividends, Record Date October 3

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   maintains XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and raises the price target from $74 to $117.</p>


HC Wainwright & Co. Maintains Buy on XOMA Royalty, Raises Price Target to $117

XOMA Q2 2024 GAAP EPS $0.84 Beats $(0.27) Estimate, Sales $11.086M Beat $8.377M Estimate

<p>The FDA will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2 to review the marketing application for <strong>Zevra Therapeutics Inc.&#8217;s </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) arimoclomol for Niemann-Pick <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39687903/zevra-announces-fda-advisory-committee-meeting-to-review-arimoclomol-for-the-treatment-of-niemann-" rel="noreferrer noopener">disease type C (NPC)</a>.</p>
<p>The application for arimoclomol has been assigned a Prescription Drug User Fee Act (PDUFA) action date of September 21, which was <a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37451763/zevra-therapeutics-provides-fda-update-on-the-pdufa-action-date-for-arimoclomol-as-a-treatment-for" rel="noreferrer noopener">extended from June 21</a>.</p>
<p>Previously <a target="_blank" href="https://investors.zevra.com/news-releases/news-release-details/correction-kempharm-announces-corporate-name-change-zevra" rel="noreferrer noopener">known</a> as KemPharm, Zevra Therapeutics acquired&nbsp;arimoclomol from <strong>Orphazyme</strong> <a target="_blank" href="https://www.benzinga.com/general/biotech/22/05/27213663/kempharm-acquires-battered-orphazymes-arimoclomol-program-for-13m" rel="noreferrer noopener">for $12.8 million</a>.&nbsp;</p>
<p>In 2021, the FDA issued a complete response letter to arimoclomol as a treatment option for <a target="_blank" href="https://www.benzinga.com/general/biotech/21/06/21621339/orphazyme-wild-party-at-risk-as-fda-rejects-its-rare-neurodegenerative-disease-drug?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29" rel="noreferrer noopener">Niemann-Pick disease type C</a>.</p>
<p>The CRL asked for additional qualitative and quantitative evidence to further support the validity and interpretation of the 5-domain NPC Clinical Severity Scale, <a target="_blank" href="https://www.benzinga.com/general/biotech/21/11/23783862/orphazyme-stock-gains-after-fda-update-on-arimoclomol-in-rare-neurodegenerative-disorder" rel="noreferrer noopener">particularly the swallow domain</a>.</p>
<p><strong>William Blair</strong> says the data supports the efficacy and safety of arimoclomol supports approval and expects significant patient advocacy at the meeting in support of approval.</p>
<p>Additionally, unlike the prior filing for arimoclomol, patient groups have already sent letters of support, including a petition from the National Niemann-Pick Disease Foundation and six other NPC advocacy and research organizations with nearly 1,000 signatures from NPC patients, caregivers, and physicians.</p>
<p>If approved, arimoclomol would represent a significant commercial opportunity for Zevra despite the ultra-rare nature of NPC. The analyst adds that NPC is believed to affect around 900 patients in the U.S., of whom an estimated 300-400 are currently diagnosed.</p>
<p>The company established a commercial infrastructure for launching Olpruva earlier this year. With about 70 patients on therapy through the early access program in the U.S., the analyst expects a strong launch.</p>
<p>This will involve converting these patients to full-launch participants and attracting new patients, many of whom have already shown interest.</p>
<p>Zevra owes modest milestones and mid-single-digit royalties to <strong>XOMA Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>). Given the ultra-orphan nature of the patient population, pricing will be a key variable for all stakeholders involved, pending approval.</p>
<p>William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/ZVRA/analyst-ratings" rel="noreferrer noopener">Outperform rating</a>.</p>
<p><strong>Price Action: </strong>ZVRA shares are up 17.4% at $5.27 at last check Tuesday.</p>


FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

<p>In the preceding three months, 5 analysts have released ratings for XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.2, with a high estimate of $74.00 and a low estimate of $40.00. This current average represents a 9.19% decrease from the previous average price target of $74.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1720533666_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive XOMA. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jason Zhuang</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to XOMA. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of XOMA compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for XOMA's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of XOMA's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on XOMA analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into XOMA's Background</h2>
<p>XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.</p>
<h3>Unraveling the Financial Story of XOMA</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining XOMA's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>240.96%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> XOMA's net margin excels beyond industry benchmarks, reaching <strong>-668.66%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-11.66%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> XOMA's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-4.39%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> XOMA's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.47</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying XOMA: Insights From 5 Analyst Reviews

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $74 price target.</p>


HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target

XOMA Disclosed It Had Received An $8.1M Milestone Payment From Viracta Therapeutics, Inc., Related To Day One Biopharmaceuticals' Recent Sale Of Its Priority Review Voucher (prv) For $108MTo An Undisclosed Buyer

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on XOMA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $67.2, with a high estimate of $74.00 and a low estimate of $40.00. A decline of 9.19% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1717156840_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of XOMA's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Zhuang</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to XOMA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of XOMA compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for XOMA's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into XOMA's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XOMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on XOMA analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering XOMA: A Closer Look</h2>
<p>XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.</p>
<h3>Unraveling the Financial Story of XOMA</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining XOMA's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>240.96%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-668.66%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> XOMA's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-11.66%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> XOMA's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-4.39%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.47</strong>, XOMA faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring XOMA Through Analyst Insights

Xoma (XOMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wain...

Strategic Positioning and Growth Potential Drive Buy Rating for Xoma

TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) today. The company's shares opened today at $31.31. Nadeau c...

Xoma (XOMA) Gets a Hold from TD Cowen

Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'

Leerink Partners analyst David Risinger has maintained their bullish stance on XOMA stock, giving a Buy rating on November 7. David Risinger has gi...

Xoma's Strategic Developments and Financial Performance Drive Buy Rating and Increased Price Target

Twist Bioscience: A Post-Earnings Assessment

XOMA (XOMA) Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension thro...

Xoma Royalty acquires Pulmokine for $20M

Strategic Acquisitions and Growth Potential Bolster Xoma's Buy Rating

H.C. Wainwright raised the firm's price target on Xoma (XOMA) to $123 from $117 and keeps a Buy rating on the shares after the company acquired Pul...

Xoma price target raised to $123 from $117 at H.C. Wainwright

TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma (XOMA – Research Report) today. The company's shares opened today at $34.78. Accordin...

Comments

XOMA Royalty

XOMA Royalty (XOMA) Forecast

XOMA Royalty (NASDAQ:XOMA) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga